

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,841,537 B1
DATED : January 11, 2005
INVENTOR(S) : Joshi et al.

Page 1 of 2

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 36,

Line 13, please replace "leading" with -- lead --.

Column 40,

Line 5, please replace "fast" with -- first --.

Line 7, please replace "front" with -- from --.

Line 11, after "step (a)," please insert -- wherein said nucleic acid is administered in a lipid formulation comprising a cationic lipid and a lipid derivative selected from the group consisting of an ATTA-lipid, a polyethylene glycol (PEG)-lipid derivative, and a ganglioside G_{M1}-modified lipid,

wherein said nucleic acid is fully encapsulated in said lipid formulation such that less than 5% of the nucleic acid is degraded after exposure of said formulation to 1 U DNase I for 30 minutes in digestion buffer at 37°C, and further --.

Column 41,

Line 2, please replace "GDEPT" with -- Gene Directed Enzyme Prodrug Therapy ("GDEPT") --.

Column 41, Line 47, please replace ", and" with --in a lipid formulation comprising a cationic lipid and a lipid derivative selected from the group consisting of an ATTA-lipid, a polyethylene glycol (PEG)-lipid derivative, and a ganglioside G_{M1}-modified lipid,

wherein said nucleic acid is fully encapsulated in said lipid formulation such that less than 5% of the nucleic acid is degraded after exposure of said formulation to 1 U DNase I for 30 minutes in digestion buffer at 37°C, and further, --.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,841,537 B1
DATED : January 11, 2005
INVENTOR(S) : Joshi et al.

Page 2 of 2

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:


Column 42,

Line 8, please replace "call" with -- cell --.

Lines 52 to 57, please delete "29. The method of claim 1, wherein said cell cycle blocking agent is selected from the group consisting of DNA alkylating agents, DNA topoisomerase inhibitors, micro-tubule disassembly inhibitors, microtubule disassembly inhibitors, DNA-cross linking agents, DNA-binding agents and nucleoside analogues."

Signed and Sealed this

Thirty-first Day of May, 2005

A handwritten signature in black ink, reading "Jon W. Dudas", is written over a rectangular grid background.

JON W. DUDAS

Director of the United States Patent and Trademark Office